Amgen, US0311621009

Amgen stock pre-market at EUR 360.03: plus 0.28 percent

Published on 10/06/2026 at 08:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock is at EUR 360.03 pre-market at Lang & Schwarz, up 0.28 percent versus the prior close of EUR 359.03. The quote was recorded at 8:36 a.m. CEST on October 6, 2026.

Editorial-Aufnahme eines Nasdaq-Handelssaals mit großen Bildschirmen und steigenden Biotech-Sektor-Kurscharts
Amgen Inc. (ISIN US0311621009) thematisiert dieses Börsen-Editorial mit Nasdaq-Handelssaal und ansteigenden Biotech-Sektor-Kurscharts auf großen Bildschirmen, Illustration mit AI erstellt.

Amgen stock is at EUR 360.03 pre-market at Lang & Schwarz at 8:36 a.m. CEST on October 6, 2026. The price is up EUR 1.00, or 0.28 percent, versus the Lang & Schwarz prior close of EUR 359.03 on October 5, 2026.

Pre-market price

The Lang & Schwarz bid was EUR 359.15 and the ask was EUR 360.90. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Amgen stock.

Previous close

Amgen stock closed at EUR 359.03 at Lang & Schwarz on October 5, 2026. The current pre-market indication is reported separately from company news.

Clinical development

Amgen said on September 22, 2026, that it had announced positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease. The company identified the study as OASIZ 301. Amgen investor relations listed the announcement among its recent news releases.

Disclaimer...

en | US0311621009 | AMGEN | boerse | 70239491 | bgmi